Exploration of Digestive Diseases

Table 1. Time of presentation of disease/onset of clinical symptoms with respect to RNA positivity.

Duration of jaundice	AVH^a HAV RNA/HAV-IgM (%)	FHF^b HAV RNA/HAV-IgM (%)
0–7 Days	38/51 (74.5)	7/7 (100)
7–14 Days	18/29 (62.1)	3/3 (100)
1–2 Months	5/11 (45.5)	-
5 Months	1/ 3 (33.3)	-

Return to article view

a: acute viral hepatitis; b: fulminant hepatic failure; HAV-IgM: serologically positive patients; HAV RNA: serologically positive samples were confirmed by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR); AVH: acute viral hepatitis; FHF: fulminant hepatic failure. Reprinted from [50]. © The Authors 2011. Licensed under a CC-BY 2.0.

Declarations

Author contributions

ZH: Conceptualization, Investigation, Supervision, Writing—original draft, Writing—review & editing. IS: Writing—review & editing, Investigation. SK: Writing—review & editing. RS: Writing—review & editing. KP: Writing—review & editing. VP: Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Koff RS. Hepatitis A. Lancet. 1998;351:1643–9. [DOI] [PubMed]

Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev. 2001;14:38–58. [DOI] [PubMed] [PMC]

Flehmig B, Frank H, Frösner GG, Gerth HJ. Hepatitis A-virus particles in stools of patients from a natural hepatitis outbreak in Germany. Med Microbiol Immunol. 1977;163:209–14. [DOI] [PubMed]

McCaustland KA, Bond WW, Bradley DW, Ebert JW, Maynard JE. Survival of hepatitis A virus in feces after drying and storage for 1 month. J Clin Microbiol. 1982;16:957–8. [DOI] [PubMed] [PMC]

Karayiannis P, Jowett T, Enticott M, Moore D, Pignatelli M, Brenes F, et al. Hepatitis A virus replication in tamarins and host immune response in relation to pathogenesis of liver cell damage. J Med Virol. 1986;18:261–76. [DOI] [PubMed]

Siegl G. Viral Hepatitis and Liver Disease. In: Zuckerman AJ, editor. Virology of hepatitis A. New York: Wiley-Liss; 1988. pp. 3–7.

Teixeira MR Jr, Weller IV, Murray A, Bamber M, Thomas HC, Sherlock S, et al. The pathology of hepatitis A in man. Liver. 1982;2:53–60. [DOI] [PubMed]

Anderson DA, Locarnini SA, Gust ID. Viral hepatitis and liver disease. In: Zuckerman AJ, editor. Replication of hepatitis A virus. New York: Wiley-Liss; 1988. pp. 8–11.

Jang SK, Davies MV, Kaufman RJ, Wimmer E. Initiation of protein synthesis by internal entry of ribosomes into the 5’ nontranslated region of encephalomyocarditis virus RNA in vivo. J Virol. 1989;63:1651–60. [DOI] [PubMed] [PMC]

10.

Funkhouser AW, Schultz DE, Lemon SM, Purcell RH, Emerson SU. Hepatitis A virus translation is rate-limiting for virus replication in MRC-5 cells. Virology. 1999;254:268–78. [DOI] [PubMed]

11.

Hussain Z. VIRAL HEPATITIS — SELECTED ISSUES OF PATHOGENESIS AND DIAGNOSTICS. In: Mukomolov SL, editor. Hepatitis A: Clinical, Epidemiological and Molecular Characteristics. Rijeka: InTech; 2011. pp. 127–40.

12.

Najarian R, Caput D, Gee W, Potter SJ, Renard A, Merryweather J, et al. Primary structure and gene organization of human hepatitis A virus. Proc Natl Acad Sci U S A. 1985;82:2627–31. [DOI] [PubMed] [PMC]

13.

Flehmig B, Normann A, Bohnen D. Transmission of hepatitis A virus infection despite vaccination. N Engl J Med. 2000;343:301–2. [DOI] [PubMed]

14.

Hussain Z. Practical Management of Chronic Viral Hepatitis. In: Serviddio G, editor. Genomic Heterogeneity of Hepatitis Viruses (A–E): Role in Clinical Implications and Treatment. Rijeka: InTech; 2013. pp. 19–56.

15.

Weitz M, Baroudy BM, Maloy WL, Ticehurst JR, Purcell RH. Detection of a genome-linked protein (VPg) of hepatitis A virus and its comparison with other picornaviral VPgs. J Virol. 1986;60:124–30. [DOI] [PubMed] [PMC]

16.

Borman AM, Kean KM. Intact eukaryotic initiation factor 4G is required for hepatitis A virus internal initiation of translation. Virology. 1997;237:129–36. [DOI] [PubMed]

17.

Emerson SU, Huang YK, Purcell RH. 2B and 2C mutations are essential but mutations throughout the genome of HAV contribute to adaptation to cell culture. Virology. 1993;194:475–80. [DOI] [PubMed]

18.

Schultheiss T, Kusov YY, Gauss-Müller V. Proteinase 3C of hepatitis A virus (HAV) cleaves the HAV polyprotein P2-P3 at all sites including VP1/2A and 2A/2B. Virology. 1994;198:275–81. [DOI] [PubMed]

19.

Totsuka A, Moritsugu Y. Hepatitis A virus proteins. Intervirology. 1999;42:63–8. [DOI] [PubMed]

20.

Harmon SA, Updike W, Jia XY, Summers DF, Ehrenfeld E. Polyprotein processing in cis and in trans by hepatitis A virus 3C protease cloned and expressed in Escherichia coli. J Virol. 1992;66:5242–7. [DOI] [PubMed] [PMC]

21.

Probst C, Jecht M, Gauss-Müller V. Processing of proteinase precursors and their effect on hepatitis A virus particle formation. J Virol. 1998;72:8013–20. [DOI] [PubMed] [PMC]

22.

Hepatitis A vaccines. Wkly Epidemiol Rec. 2000;75:38–44. [PubMed]

23.

Shapiro CN, Margolis HS. Worldwide epidemiology of hepatitis A virus infection. J Hepatol. 1993;18 Suppl 2:S11–4. [DOI] [PubMed]

24.

Szmuness W, Dienstag JL, Purcell RH, Harley EJ, Stevens CE, Wong DC. Distribution of antibody to hepatitis a antigen in urban adult populations. N Engl J Med. 1976;295:755–9. [DOI] [PubMed]

25.

Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev. 2006;28:101–11. [DOI] [PubMed]

26.

Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653–7. [DOI] [PubMed]

27.

Ogholikhan S, Schwarz KB. Hepatitis Vaccines. Vaccines (Basel). 2016;4:6. [DOI] [PubMed] [PMC]

28.

Das K, Jain A, Gupta S, Kapoor S, Gupta RK, Chakravorty A, et al. The changing epidemiological pattern of hepatitis A in an urban population of India: emergence of a trend similar to the European countries. Eur J Epidemiol. 2000;16:507–10. [DOI] [PubMed]

29.

Hussain Z, Das BC, Husain SA, Murthy NS, Kar P. Increasing trend of acute hepatitis A in north India: need for identification of high-risk population for vaccination. J Gastroenterol Hepatol. 2006;21:689–93. [DOI] [PubMed]

30.

Agrawal A, Singh S, Kolhapure S, Hoet B, Arankalle V, Mitra M. Increasing Burden of Hepatitis A in Adolescents and Adults and the Need for Long-Term Protection: A Review from the Indian Subcontinent. Infect Dis Ther. 2019;8:483–97. [DOI] [PubMed] [PMC]

31.

Grover M, Gupta E, Samal J, Prasad M, Prabhakar T, Chhabra R, et al. Rising trend of symptomatic infections due to Hepatitis A virus infection in adolescent and adult age group: An observational study from a tertiary care liver institute in India. Indian J Med Microbiol. 2024;50:100653. [DOI] [PubMed]

32.

Jain M. Rising incidence of acute viral hepatitis A in young adults — A cause for concern! Indian J Gastroenterol. 2025;44:259–60. [DOI] [PubMed]

33.

Maguire H, Heptonstall J, Begg NT. The epidemiology and control of hepatitis A. Commun Dis Rep CDR Rev. 1992;2:R114–7. [PubMed]

34.

Thapa BR, Singh K, Singh V, Broor S, Singh V, Nain CK. Pattern of hepatitis A and hepatitis B virus markers in cases of acute sporadic hepatitis and in healthy school children from north west India. J Trop Pediatr. 1995;41:328–9. [DOI] [PubMed]

35.

Lemon SM. Type A viral hepatitis: epidemiology, diagnosis, and prevention. Clin Chem. 1997;43:1494–9. [PubMed]

36.

Arankalle VA, Chadha MS, Chitambar SD, Walimbe AM, Chobe LP, Gandhe SS. Changing epidemiology of hepatitis A and hepatitis E in urban and rural India (1982–98). J Viral Hepat. 2001;8:293–303. [DOI] [PubMed]

37.

Chadha MS, Chitambar SD, Shaikh NJ, Arankalle VA. Exposure of Indian children to hepatitis A virus & vaccination age. Indian J Med Res. 1999;109:11–5. [PubMed]

38.

Amin M, Siddique L, Slatter M, Biswas K. Increasing incidence of hepatitis A in Bangladesh. Bangladesh J. Sci. Ind. Res. 2012;47:309–12.

39.

Dahanayaka NJ, Kiyohara T, Agampodi SB, Samaraweera PK, Kulasooriya GK, Ranasinghe JC, et al. Clinical Features and Transmission Pattern of Hepatitis A: An Experience from a Hepatitis A Outbreak Caused by Two Cocirculating Genotypes in Sri Lanka. Am J Trop Med Hyg. 2016;95:908–14. [DOI] [PubMed] [PMC]

40.

Gupta BP, Adhikari A, Chaudhary S. Hepatitis viruses in Kathmandu, Nepal: hospital-based study. BMC Res Notes. 2018;11:627. [DOI] [PubMed] [PMC]

41.

Khan AI, Salimuzzaman M, Islam MT, Afrad MH, Shirin T, Jony MHK, et al. Nationwide Hospital-Based Seroprevalence of Hepatitis A and Hepatitis E Virus in Bangladesh. Ann Glob Health. 2020;86:29. [DOI] [PubMed] [PMC]

42.

Shahid Y, Butt AS, Jamali I, Ismail FW. Rising incidence of acute hepatitis A among adults and clinical characteristics in a tertiary care center of Pakistan. World J Virol. 2025;14:97482. [DOI] [PubMed] [PMC]

43.

Yotsuyanagi H, Iino S, Koike K, Yasuda K, Hino K, Kurokawa K. Duration of viremia in human hepatitis A viral infection as determined by polymerase chain reaction. J Med Virol. 1993;40:35–8. [DOI] [PubMed]

44.

Hussain Z, Das BC, Husain SA, Asim M, Chattopadhyay S, Malik A, et al. Hepatitis A viral genotypes and clinical relevance: Clinical and molecular characterization of hepatitis A virus isolates from northern India. Hepatol Res. 2005;32:16–24. [DOI] [PubMed]

45.

Arankalle VA, Sarada Devi KL, Lole KS, Shenoy KT, Verma V, Haneephabi M. Molecular characterization of hepatitis A virus from a large outbreak from Kerala, India. Indian J Med Res. 2006;123:760–9. [PubMed]

46.

Fujiwara K, Yokosuka O, Ehata T, Imazeki F, Saisho H, Miki M, et al. Frequent detection of hepatitis A viral RNA in serum during the early convalescent phase of acute hepatitis A. Hepatology. 1997;26:1634–9. [DOI] [PubMed]

47.

Costa-Mattioli M, Cristina J, Romero H, Perez-Bercof R, Casane D, Colina R, et al. Molecular evolution of hepatitis A virus: a new classification based on the complete VP1 protein. J Virol. 2002;76:9516–25. [DOI] [PubMed] [PMC]

48.

Arauz-Ruiz P, Sundqvist L, García Z, Taylor L, Visoná K, Norder H, et al. Presumed common source outbreaks of hepatitis A in an endemic area confirmed by limited sequencing within the VP1 region. J Med Virol. 2001;65:449–56. [PubMed]

49.

Ching KZ, Nakano T, Chapman LE, Demby A, Robertson BH. Genetic characterization of wild-type genotype VII hepatitis A virus. J Gen Virol. 2002;83:53–60. [DOI] [PubMed]

50.

Hussain Z, Husain SA, Almajhdi FN, Kar P. Immunological and molecular epidemiological characteristics of acute and fulminant viral hepatitis A. Virol J. 2011;8:254. [DOI] [PubMed] [PMC]

51.

Cohen JI, Ticehurst JR, Purcell RH, Buckler-White A, Baroudy BM. Complete nucleotide sequence of wild-type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. J Virol. 1987;61:50–9. [DOI] [PubMed] [PMC]

52.

Robertson BH, Jansen RW, Khanna B, Totsuka A, Nainan OV, Siegl G, et al. Genetic relatedness of hepatitis A virus strains recovered from different geographical regions. J Gen Virol. 1992;73:1365–77. [DOI] [PubMed]

53.

Hussain Z, Husain SA, Pasha ST, Anand R, Chand A, Polipalli SK, et al. Does mutation of hepatitis A virus exist in North India? Dig Dis Sci. 2008;53:506–10. [DOI] [PubMed]

54.

Aragonès L, Bosch A, Pintó RM. Hepatitis A virus mutant spectra under the selective pressure of monoclonal antibodies: codon usage constraints limit capsid variability. J Virol. 2008;82:1688–700. [DOI] [PubMed] [PMC]

55.

Pérez-Sautu U, Costafreda MI, Caylà J, Tortajada C, Lite J, Bosch A, et al. Hepatitis a virus vaccine escape variants and potential new serotype emergence. Emerg Infect Dis. 2011;17:734–7. [DOI] [PubMed] [PMC]

56.

Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, Mottram K, et al. The diverse patterns of hepatitis A epidemiology in the United States—implications for vaccination strategies. J Infect Dis. 1998;178:1579–84. [DOI] [PubMed]

57.

Hutin YJ, Bell BP, Marshall KL, Schaben CP, Dart M, Quinlisk MP, et al. Identifying target groups for a potential vaccination program during a hepatitis A communitywide outbreak. Am J Public Health. 1999;89:918–21. [DOI] [PubMed] [PMC]

58.

Cotter SM, Sansom S, Long T, Koch E, Kellerman S, Smith F, et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis. 2003;187:1235–40. [DOI] [PubMed]

59.

Vong S, Fiore AE, Haight DO, Li J, Borgsmiller N, Kuhnert W, et al. Vaccination in the county jail as a strategy to reach high risk adults during a community-based hepatitis A outbreak among methamphetamine drug users. Vaccine. 2005;23:1021–8. [DOI] [PubMed]

60.

Fujiwara K, Yokosuka O, Imazeki F, Saisho H, Saotome N, Suzuki K, et al. Analysis of the genotype-determining region of hepatitis A viral RNA in relation to disease severities. Hepatol Res. 2003;25:124–34. [DOI] [PubMed]

61.

Jeong SH, Lee HS. Hepatitis A: clinical manifestations and management. Intervirology. 2010;53:15–9. [DOI] [PubMed]

62.

Kanda T, Jeong S, Imazeki F, Fujiwara K, Yokosuka O. Analysis of 5’ nontranslated region of hepatitis A viral RNA genotype I from South Korea: comparison with disease severities. PLoS One. 2010;5:e15139. [DOI] [PubMed] [PMC]

63.

Mackiewicz V, Cammas A, Desbois D, Marchadier E, Pierredon S, Beaulieux F, et al. Nucleotide variability and translation efficiency of the 5’ untranslated region of hepatitis A virus: update from clinical isolates associated with mild and severe hepatitis. J Virol. 2010;84:10139–47. [DOI] [PubMed] [PMC]

64.

Hussain Z, Das BC, Husain SA, Polipalli SK, Ahmed T, Begum N, et al. Virological course of hepatitis A virus as determined by real time RT-PCR: Correlation with biochemical, immunological and genotypic profiles. World J Gastroenterol. 2006;12:4683–8. [DOI] [PubMed] [PMC]

65.

Wang M, Feng Z. Mechanisms of Hepatocellular Injury in Hepatitis A. Viruses. 2021;13:861. [DOI] [PubMed] [PMC]

66.

Vallbracht A, Gabriel P, Maier K, Hartmann F, Steinhardt HJ, Müller C, et al. Cell-mediated cytotoxicity in hepatitis A virus infection. Hepatology. 1986;6:1308–14. [DOI] [PubMed]

67.

Stapleton JT. Host immune response to hepatitis A virus. J Infect Dis. 1995;171 Suppl 1:S9–14. [DOI] [PubMed]

68.

Craig AS, Schaffner W. Prevention of hepatitis A with the hepatitis A vaccine. N Engl J Med. 2004;350:476–81. [DOI] [PubMed]

69.

Migueres M, Lhomme S, Izopet J. Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment. Viruses. 2021;13:1900. [DOI] [PubMed] [PMC]